文献速递糖尿病

1型糖尿病胰岛素泵输注部位的评估:DERMIS研究

Evaluation of Insulin Pump Infusion Sites in Type 1 Diabetes: The DERMIS Study.
PubMed 文献 · Diabetes Care · 2023-01-01

DERMIS研究采用横断面设计,使用光学相干断层扫描(OCT)、OCT血管成像(OCTA)和皮肤活检评估1型糖尿病患者慢性胰岛素输注的皮肤改变。结果显示,与对照部位相比,泵部位存在炎症增加和血管密度增高的特征,组织学分析显示纤维化、炎症(包括组织嗜酸性粒细胞增多)和脂肪坏死。作者认为这些发现支持过敏性致敏是持续皮下胰岛素输注(CSII)部位常见的反应。

要点

  • OCT和OCTA显示泵部位较对照部位有炎症增加和血管密度增高的特征。
  • 泵部位组织学分析显示皮肤结构差异,包括纤维化、炎症(组织嗜酸性粒细胞增多)和脂肪坏死。
  • 免疫组化显示输注部位与对照部位在ILGF-I和转化生长因子-β3染色上存在差异。

核心结论

  • 这些发现支持过敏性致敏是CSII部位一种可能常见的反应。
  • 引起该反应的leading候选因素包括胰岛素防腐剂、塑料材料和器械制造中使用的粘合胶。
  • 这些常见过敏反应引起的炎症反应可能导致组织改变,从而造成临床实践中常见的输注部位故障。

研究设计与样本

  • 横断面研究,使用中心波长1,310 nm、带宽100 nm的OCT,在皮肤钻孔活检前立即对三个部位进行检查:当前部位(OCT和活检时移除输注装置)、恢复部位(活检前3天移除输注装置)和对照部位(从未用于任何胰岛素输注或注射)。

主要发现

  • OCT和OCTA识别出泵部位与对照部位相比炎症增加和血管密度增高的特征。
  • 泵部位的组织学分析显示皮肤结构差异,包括纤维化、炎症(包括组织嗜酸性粒细胞增多)和脂肪坏死。
  • 免疫组化染色显示输注部位与对照部位在ILGF-I和转化生长因子-β3染色上存在差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Continuous subcutaneous insulin infusion (CSII) for type 1 diabetes is increasing in use. Pump site failures are common, but little is known about skin changes from pump use. Using noninvasive optical coherence tomography (OCT), OCT angiography (OCTA), and skin biopsies, we evaluated skin changes from chronic insulin infusion. RESEARCH DESIGN AND METHODS: In this cross-sectional study, OCT operating at a 1,310-nm central wavelength with a bandwidth of 100 nm was performed immediately before skin punch biopsies were collected at three sites: the current site, with the infusion set removed at time of OCT and biopsy; the recovery site, with the infusion set removed 3 days before biopsy; and the control site, which was never used for any insulin infusion or injection. RESULTS: OCT and OCTA identified characteristics of increased inflammation and vessel density at pump sites compared with control sites. Histologic analysis of pump sites showed differences in skin architecture, including fibrosis, inflammation (including increased tissue eosinophils), and fat necrosis. Immunohistochemical staining showed differences between infusion and control sites regarding staining of ILGF-I and transforming growth factor-β3. CONCLUSIONS: These findings support allergic sensitization as a potentially common reaction at CSII sites. The leading candidates causing this include insulin preservatives, plastic materials, and adhesive glue used in device manufacturing. The inflammatory response caused by these common allergic responses may result in tissue changes responsible for the infusion site failures seen frequently in clinical practice.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kalus A, Shinohara MM, Wang R, et al. Evaluation of Insulin Pump Infusion Sites in Type 1 Diabetes: The DERMIS Study. Diabetes Care. 2023. PMID: 37450710. doi:10.2337/dc23-0426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。